Significant Pathways

CBI-Knowledgebase for Addiction Related Genes

KARG >> Addiction Related Pathways

Several addiction-enriched KEGG pathways including both metabolic pathways and signalling pathways have been identified by KOBAS (KEGG Orthology-Based Annotation System), an automatic annotation system to annotate a set of nucleotide or protein sequences with KEGG Orthology terms based on BLAST similarity search against KEGG GENES(Mao et al, Bioinformatics, 2005). To cite this work, please refer to: Li CY, Mao X, Wei L (2008) Genes and (common) pathways underlying drug addiction. PLoS Comput Biol 4(1): e2. doi:10.1371/journal.pcbi.0040002

Common Molecular Pathways for Drug Addiction

Addictive Drugs	COCAINE	ALCOHOL	OPIOIDS	NICOTINE
Neuroactive ligand-receptor interaction
P-Values	5.39E-05**	3.24E-02*	2.68E-03**	7.79E-03**
Q-Values	1.8E-04**	0.05*	0.01*	0.04*
Long-term potentiation
P-Values	3.21E-08**	8.28E-03**	1.05E-02*	8.84E-03**
Q-Values	2.8E-07**	0.03*	0.03*	0.04*
GnRH signaling pathway
P-Values	2.84E-05**	3.93E-04**	4.67E-03**	1.72E-02*
Q-Values	1.2E-04**	3.6E-03**	0.02*	0.05*
MAPK signaling pathway
P-Values	1.28E-04**	2.97E-04**	7.34E-05**	1.10E-02*
Q-Values	3.7E-04**	3.6E-03**	5.2E-04**	0.04*
Gap junctions
P-Values	1.93E-08**	3.11E-03**	3.30E-03**	5.85E-03**
Q-Values	2.8E-07**	0.01**	0.01**	0.03*

KEGG Pathways for Drug Addiction (Using 396 gene sets)

Long-term depression	2.1E-07**	1.1E-05**
Gap junction	1.5E-07**	1.1E-05**
Long-term potentiation	3.5E-06**	7.2E-05**
Neuroactive ligand-receptor interaction	2.1E-06**	7.2E-05**
MAPK signaling pathway	3.1E-06**	7.2E-05**
GnRH signaling pathway	8.5E-06**	1.5E-04**
Calcium signaling pathway	4.8E-04**	7.0E-03**
Colorectal cancer	6.5E-04**	8.3E-03**
Pores ion channels	2.1E-03**	0.02*
VEGF signaling pathway	3.2E-03**	0.03*
Glycolysis /Gluconeogenesis	3.8E-03**	0.03*
Protein folding and associated processing	3.8E-03**	0.03*
Focal adhesion	4.4E-03**	0.03*
Insulin signaling pathway	4.9E-03**	0.03*
Parkinson's disease	6.3E-03**	0.04*
Fc epsilon RI signaling pathway	6.9E-03**	0.04*
Type II diabetes mellitus	7.7E-03**	0.05*
Progesterone-mediated oocyte maturation	9.1E-03**	0.05*

KEGG Pathways for Drug Addiction (Using 1500 gene sets)

Long-term potentiation	3.05E-08**	4.44E-06**
Gap junction	5.13E-08**	4.44E-06**
Long-term depression	6.75E-06**	3.89E-04**
Neuroactive ligand-receptor interaction	2.04E-05**	6.67E-04**
MAPK signaling pathway	2.66E-05**	6.67E-04**
GnRH signaling pathway	2.70E-05**	6.67E-04**
Calcium signaling pathway	1.58E-05**	6.67E-04**
Amyotrophic lateral sclerosis (ALS)	3.86E-05**	8.35E-04**
Colorectal cancer	9.18E-04**	1.59E-02*
Progesterone-mediated oocyte maturation	8.29E-04**	1.59E-02*
Type I diabetes mellitus	1.16E-03**	1.82E-02*
Oxidative phosphorylation	1.34E-03**	1.93E-02*
Stilbene, coumarine and lignin biosynthesis	1.63E-03**	2.13E-02*
Pores ion channels	1.72E-03**	2.13E-02*
Type II diabetes mellitus	2.03E-03**	2.34E-02*
Focal adhesion	2.76E-03**	2.99E-02*
Parkinson's disease	3.49E-03**	3.55E-02*
Glutamate metabolism	5.36E-03**	5.15E-02

In these tables, ‘*’ indicates a P-Value/Q-Value less than 0.05, ‘**’ indicates a P-Value/Q-Value less than 0.01.

Any Comments and suggestions to : KARG GROUP.